Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

What is the best PET target for early biochemical recurrence of prostate cancer?

Andriole GL.

Lancet Oncol. 2019 Nov;20(11):e608. doi: 10.1016/S1470-2045(19)30586-8. No abstract available.

PMID:
31674313
2.

The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.

Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G.

Minerva Urol Nefrol. 2018 Oct;70(5):462-478. doi: 10.23736/S0393-2249.18.03081-3. Epub 2018 Apr 17. Review.

3.

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.

Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613.

PMID:
31375469
4.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
5.

Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.

Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-1655. doi: 10.1007/s00259-017-3743-z. Epub 2017 Jun 6.

PMID:
28589253
6.

Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.

Krause BJ, Souvatzoglou M, Treiber U.

Urol Oncol. 2013 May;31(4):427-35. doi: 10.1016/j.urolonc.2010.08.008. Epub 2011 Mar 8. Review.

PMID:
21388835
7.

[Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].

Poncet D, Arnoux V, Descotes JL, Rambeaud JJ, Verry C, Terrier N, Boillot B, Dubreuil J, Lanchon C, Carnicelli D, Fiard G, Long JA.

Prog Urol. 2015 May;25(6):325-30. doi: 10.1016/j.purol.2015.01.018. Epub 2015 Mar 5. French.

PMID:
25748788
8.

[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.

Green MA, Hutchins GD, Bahler CD, Tann M, Mathias CJ, Territo W, Sims J, Polson H, Alexoff D, Eckelman WC, Kung HF, Fletcher JW.

Mol Imaging Biol. 2019 Aug 19. doi: 10.1007/s11307-019-01421-7. [Epub ahead of print]

PMID:
31429050
9.

The use of 68  Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.

Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.

BJU Int. 2016 Oct;118 Suppl 3:49-55. doi: 10.1111/bju.13616. Epub 2016 Sep 23.

10.

Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.

Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):960-968. doi: 10.1007/s00259-017-3669-5. Epub 2017 Mar 9.

PMID:
28280856
11.

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19. doi: 10.1007/s00259-018-4066-4. Epub 2018 Jun 15.

PMID:
29905907
12.

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.

Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.

Eur Urol. 2018 May;73(5):656-661. doi: 10.1016/j.eururo.2018.01.006. Epub 2018 Jan 19.

PMID:
29358059
13.

Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.

Colombié M, Campion L, Bailly C, Rusu D, Rousseau T, Mathieu C, Ferrer L, Rousseau N, Kraeber-Bodéré F, Rousseau C.

Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1784-93. doi: 10.1007/s00259-015-3123-5. Epub 2015 Jul 21.

PMID:
26194716
14.

What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J.

Lancet Oncol. 2019 Nov;20(11):e609-e610. doi: 10.1016/S1470-2045(19)30654-0. No abstract available.

PMID:
31674314
15.

Role of PET-CT with 18F-fluorocholine in biochemical recurrence after treatment of prostate cancer with curative intent.

Puche-Sanz I, Triviño-Ibáñez E, Vázquez-Alonso F, Llamas-Elvira JM, Cózar-Olmo JM, Rodríguez-Fernández A.

Actas Urol Esp. 2017 Sep;41(7):437-444. doi: 10.1016/j.acuro.2017.02.002. Epub 2017 Apr 25. English, Spanish.

PMID:
28389027
16.

Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.

Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG, Kendler D, von Guggenberg E, Bektic J, Horninger W, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2017 May;44(5):765-775. doi: 10.1007/s00259-016-3578-z. Epub 2016 Nov 29.

PMID:
27900519
17.

Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.

Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W.

J Nucl Med. 2013 Jun;54(6):833-40. doi: 10.2967/jnumed.112.110148. Epub 2013 Apr 4.

18.

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, Schuster T, Geinitz H, Treiber U, Schwaiger M.

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):18-23. Epub 2007 Sep 22.

PMID:
17891394
19.

[Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].

Veliev EI, Tomilov AA, Goncharuk DA, Bogdanov AB, Golubtsova EN.

Urologiia. 2018 Jul;(3):105-110. Russian.

PMID:
30035428
20.

Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer.

Galgano SJ, Valentin R, McConathy J.

Transl Androl Urol. 2018 Sep;7(Suppl 4):S462-S476. doi: 10.21037/tau.2018.06.09. Review.

Supplemental Content

Support Center